机构：[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing 10050, China研究所北京市神经外科研究所首都医科大学附属天坛医院[2]Beijing Tiantan Hospital, Capital Medical University, Beijing 10050, China首都医科大学附属天坛医院[3]Beijing Institute for Brain Disorders Brain Tumor Center, China National Clinical Research Center for Neurological Diseases, Key Laboratory of Central Nervous System Injury Research, Capital Medical University, Beijing10050, China
Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets. Recently, studies have suggested that epidermal growth factor-like domain 7 (EGFL7) can promote tumor growth, invasion, and angiogenesis. We previously reported that overexpression of EGFL7 might play a crucial role in hormone-producing pituitary adenomas. In the present study, we now demonstrated a significantly higher protein expression of EGFL7 in prolactinoma compared with the normal pituitary gland. However, inhibition of EGFL7 with antiEGFL7 antibodies significantly reduced the proliferation and PRL secretion of rat prolactinoma MMQ cells. Notably, in vitro administration of anti-EGFL7 antibodies significantly induced MMQ cells apoptosis in a dosedependent manner. In conclusion, our finding suggests that EGFL7 is significantly overexpressed in prolactinoma and inhibition of EGFL7 with antibodies promoted MMQ cells apoptosis and inhibited PRL secretion. Thus, EGFL7 may serve as a potential novel therapeutic target for prolactinomas.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502154]; Research Special Fund For Public Welfare Industry of Health of China [201402008]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2015AA020504]
第一作者机构：[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing 10050, China[2]Beijing Tiantan Hospital, Capital Medical University, Beijing 10050, China[3]Beijing Institute for Brain Disorders Brain Tumor Center, China National Clinical Research Center for Neurological Diseases, Key Laboratory of Central Nervous System Injury Research, Capital Medical University, Beijing10050, China
通讯作者：
通讯机构：[*1]Beijing Neurosurgical Institute, Capital Medical University, Beijing 10050, China[*2]Beijing Tiantan Hospital, Capital Medical University, Beijing 10050, China[*3]Beijing Institute for Brain Disorders Brain Tumor Center, China National Clinical Research Center for Neurological Diseases, Key Laboratory of Central Nervous System Injury Research, Capital Medical University, Beijingl0050, China
推荐引用方式(GB/T 7714)：
Qian Liu,Taoyang Yuan,Hua Gao,et al.Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion[J].OPEN CHEMISTRY.2018,16(1):621-626.doi:10.1515/chem-2018-0064.
APA：
Qian Liu,Taoyang Yuan,Hua Gao,Songbai Gui,Yazhuo Zhang&Chuzhong Li.(2018).Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion.OPEN CHEMISTRY,16,(1)
MLA：
Qian Liu,et al."Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion".OPEN CHEMISTRY 16..1(2018):621-626
